The so-called booster dose of Covid-19 vaccine continues to provide strong protection to the elderly almost 4 months after the third dose, according to new data released today by the British health authorities.
The efficacy of the vaccine (against severe disease requiring hospitalization) for those over 65 years, 15 weeks after the booster dose was estimated at 85%, from 91% two weeks after the third dose, according to the latest vaccination program monitoring report in the UK.
These data are the first to be published in the UK regarding the long-term resistance of booster doses of Covid-19 vaccines. The British authorities are giving a fourth dose to vulnerable age groups, as is the case in other countries (eg Israel), as people are confronted with the highly contagious Omicron variant of the coronavirus.
A fourth dose is given 6 months after the third, and a broader fall campaign is being considered.
The report attempts to distinguish between patients who have been hospitalized for Covid and those who have been hospitalized for another illness and tested positive for routine tests. Patients with respiratory problems were considered, suggesting that their introduction was most likely related to Covid-19.
For people aged 18-64 years, the effectiveness of the vaccine against severe disease seems to decline more: 15 weeks after the booster dose, it was estimated at 67% compared with 88% two weeks after the third dose.
However, British health officials say this is most likely due to the fact that younger people are more likely to be hospitalized for other reasons and also have Covid, creating a misconception that vaccines are less effective.
The report reiterates that protection against the onset of symptoms decreases more dramatically for all age groups: from 60-75% efficacy 2-4 weeks after the booster dose … to 25-40% after 15 weeks.
Vaccines developed mainly by Pfizer / BioNTech, Moderna and AstraZeneca have been given in Britain. The so-called booster dose program, which began in September, includes Pfizer / BioNTech and Moderna formulations.
Source: ΑΠΕ-ΜΠΕ
Source: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
